Lian F. Van Der Gang

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Dupilumab in prurigo nodularis: 52-week effectiveness and safety from the prospective multicenter BioDay registry.

Dupilumab in prurigo nodularis: 52-week effectiveness and safety from the prospective multicenter BioDay registry.

Journal: Journal of the American Academy of Dermatology
Published: March 20, 2026

Dupilumab in prurigo nodularis: 52-Week effectiveness and safety from the prospective multicenter BioDay registry.

Dupilumab in prurigo nodularis: 52-Week effectiveness and safety from the prospective multicenter BioDay registry.

Journal: Journal of the American Academy of Dermatology
Published: March 20, 2026

Translating 6-year trial safety data of upadacitinib in atopic dermatitis into clinical practice.

Translating 6-year trial safety data of upadacitinib in atopic dermatitis into clinical practice.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 25, 2026

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay.

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 15, 2026

Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis.

Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 22, 2025

Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment.

Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment.

Journal: Expert opinion on biological therapy
Published: December 01, 2025

Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real-world evidence.

Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real-world evidence.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 02, 2025

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry.

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry.

Journal: Allergy
Published: July 29, 2025

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results.

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 19, 2024

Single-cell sequencing of human Langerhans cells identifies altered gene expression profiles in patients with atopic dermatitis.

Single-cell sequencing of human Langerhans cells identifies altered gene expression profiles in patients with atopic dermatitis.

Journal: ImmunoHorizons
Published: November 13, 2024

Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.

Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.

Journal: JAMA dermatology
Published: August 07, 2024

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment.

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: June 21, 2024
Showing 1-12 of 16

Last Updated: 09/26/2026